PF-06412562

Last updated

PF-06412562
Clinical data
Other namesPF06412562; PF-6412562; PF6412562; CVL-562; CVL562
Routes of
administration 		Oral [1]
Drug class Dopamine D1 and D5 receptor agonist
Identifiers
  • 4-[4-(4,6-dimethylpyrimidin-5-yl)-3-methylphenoxy]-1H-pyrazolo[4,5-c]pyridine
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
Formula C19H17N5O
Molar mass 331.379 g·mol−1
3D model (JSmol)
  • CC1=C(C=CC(=C1)OC2=NC=CC3=C2C=NN3)C4=C(N=CN=C4C)C
  • InChI=1S/C19H17N5O/c1-11-8-14(25-19-16-9-23-24-17(16)6-7-20-19)4-5-15(11)18-12(2)21-10-22-13(18)3/h4-10H,1-3H3,(H,23,24)
  • Key:IDIUJOHYYBNCPC-UHFFFAOYSA-N

PF-06412562, also known as CVL-562, is a moderately potent and highly selective dopamine D1 and D5 receptor partial agonist which is under development for the treatment of the cognitive symptoms of schizophrenia. [1] [2] [3] [4] It is taken orally. [1] The drug has been reported to produce pro-motivational effects in humans. [3] [5] PF-06412562 is under development by Pfizer and Cerevel Therapeutics. [1] [2] As of August 2025, it is in phase 1/2 clinical trials. [1] [2] The drug was also under development for the treatment of Parkinson's disease and cognition disorders, but development for these indications was discontinued. [1] [2] Its development for Parkinson's disease was discontinued for business reasons unrelated to safety in 2017. [6]

See also

References

  1. 1 2 3 4 5 6 "PF 6412562". AdisInsight. 5 August 2024. Retrieved 28 January 2026.
  2. 1 2 3 4 Keown A (4 December 2025). "Delving into the Latest Updates on PF-06412562 with Synapse". Synapse. Retrieved 28 January 2026.
  3. 1 2 Abi-Dargham A, Javitch JA, Slifstein M, Anticevic A, Calkins ME, Cho YT, et al. (January 2022). "Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia". Schizophrenia Bulletin. 48 (1): 199–210. doi:10.1093/schbul/sbab095. PMC   8781338 . PMID   34423843.
  4. ↑ Jing XZ, Yang HJ, Taximaimaiti R, Wang XP (2023). "Advances in the Therapeutic Use of Non-Ergot Dopamine Agonists in the Treatment of Motor and Non-Motor Symptoms of Parkinson's Disease". Current Neuropharmacology. 21 (5): 1224–1240. doi:10.2174/1570159X20666220915091022. PMC   10286583 . PMID   36111769.
  5. ↑ Soutschek A, Gvozdanovic G, Kozak R, Duvvuri S, de Martinis N, Harel B, et al. (April 2020). "Dopaminergic D1 Receptor Stimulation Affects Effort and Risk Preferences". Biological Psychiatry. 87 (7): 678–685. doi:10.1016/j.biopsych.2019.09.002. PMID   31668477.
  6. ↑ Hall A, Provins L, Valade A (January 2019). "Novel Strategies To Activate the Dopamine D1 Receptor: Recent Advances in Orthosteric Agonism and Positive Allosteric Modulation". Journal of Medicinal Chemistry. 62 (1): 128–140. doi:10.1021/acs.jmedchem.8b01767. PMID   30525590.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.